CL2016001507A1 - Compuestos para tratar pacientes con células cancerosas mutantes ros1 - Google Patents

Compuestos para tratar pacientes con células cancerosas mutantes ros1

Info

Publication number
CL2016001507A1
CL2016001507A1 CL2016001507A CL2016001507A CL2016001507A1 CL 2016001507 A1 CL2016001507 A1 CL 2016001507A1 CL 2016001507 A CL2016001507 A CL 2016001507A CL 2016001507 A CL2016001507 A CL 2016001507A CL 2016001507 A1 CL2016001507 A1 CL 2016001507A1
Authority
CL
Chile
Prior art keywords
compounds
cancer cells
cancer
treating patients
mutant cancer
Prior art date
Application number
CL2016001507A
Other languages
English (en)
Inventor
Jonathan Lim
Elena Ardini
Maria Menichincheri
Original Assignee
Nerviano Medical Sciences Srl
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl, Ignyta Inc filed Critical Nerviano Medical Sciences Srl
Publication of CL2016001507A1 publication Critical patent/CL2016001507A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>USO DE COMPUESTOS N-(1H-INDAZOL-3-IL)-4-(PIPERAZIN-1-IL)-BENZAMIDA SUSTITUIDOS O SUS SALES PARA TRATAR CANCER PULMONAR DE CELULAS NO PEQUENAS, CANCER PAPILAR DE LA TIROIDES, NEUROBLASTOMA, CANCER PARICREATICO Y CANCER COLORRECTAL, CON AL MENOS UNA ALTERACION GENETICA EN AL MENOS UN GEN OBJETIVO ROS1, NTRK1, NTRK2 Y NTRK3.</p>
CL2016001507A 2014-02-20 2016-06-15 Compuestos para tratar pacientes con células cancerosas mutantes ros1 CL2016001507A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461942287P 2014-02-20 2014-02-20
US201462052994P 2014-09-19 2014-09-19
US201462055450P 2014-09-25 2014-09-25
US201462069999P 2014-10-29 2014-10-29

Publications (1)

Publication Number Publication Date
CL2016001507A1 true CL2016001507A1 (es) 2017-02-10

Family

ID=52544499

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001507A CL2016001507A1 (es) 2014-02-20 2016-06-15 Compuestos para tratar pacientes con células cancerosas mutantes ros1

Country Status (20)

Country Link
US (4) US10231965B2 (es)
EP (2) EP3834827A1 (es)
JP (1) JP6636933B2 (es)
KR (2) KR102634514B1 (es)
CN (1) CN106029073A (es)
AU (1) AU2015220832B2 (es)
BR (1) BR112016015818A2 (es)
CA (1) CA2933623C (es)
CL (1) CL2016001507A1 (es)
EA (1) EA033457B1 (es)
ES (1) ES2856231T3 (es)
IL (1) IL246544B (es)
MX (1) MX2016010519A (es)
NL (1) NL301111I2 (es)
PH (1) PH12016501394A1 (es)
PL (1) PL3107541T3 (es)
SG (1) SG11201605816TA (es)
TW (1) TWI672141B (es)
UA (1) UA118773C2 (es)
WO (1) WO2015124697A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CR20170098A (es) 2010-05-20 2017-07-17 Array Biopharma Inc Compuestos macrociclicos como inhibidores de quinasa trk
SG10201700808UA (en) 2013-02-19 2017-02-27 Ono Pharmaceutical Co Trk-INHIBITING COMPOUND
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
JP6914834B2 (ja) 2014-11-16 2021-08-04 アレイ バイオファーマ インコーポレイテッド （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形
KR102595599B1 (ko) 2014-12-02 2023-11-02 이그니타, 인코포레이티드 신경모세포종의 치료를 위한 병용
EP3227686A4 (en) * 2014-12-03 2018-08-29 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
EA201792679A1 (ru) 2015-06-01 2018-06-29 Локсо Онколоджи, Инк. Способы диагностики и лечения злокачественной опухоли
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
AU2016344058A1 (en) 2015-10-26 2018-05-17 Array Biopharma Inc. Point mutations in Trk inhibitor-resistant cancer and methods relating to the same
WO2017106492A1 (en) * 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
RU2751767C2 (ru) 2016-04-04 2021-07-16 Локсо Онколоджи, Инк. Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
LT3439663T (lt) 2016-04-04 2024-10-10 Loxo Oncology, Inc. Vaikų vėžio gydymo būdai
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
JP7094228B2 (ja) 2016-05-24 2022-07-01 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｎ－［５－（３，５－ジフルオロ－ベンジル）－１ｈ－インダゾール－３－イル］－４－（４－メチル－ピペラジン－１－イル）－２－（テトラヒドロ－ピラン－４－イルアミノ）－ベンズアミドの新規結晶形
JP2019527231A (ja) * 2016-08-01 2019-09-26 イグナイタ インコーポレイテッド がんを治療するための組み合わせ
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10398693B2 (en) 2017-07-19 2019-09-03 Ignyta, Inc. Pharmaceutical compositions and dosage forms
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CN111225662B (zh) * 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
EP3700576A1 (en) 2017-10-26 2020-09-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
MA52218A (fr) 2018-03-29 2021-02-17 Loxo Oncology Inc Traitement de cancers associés à trk
CN113194928A (zh) 2018-07-31 2021-07-30 罗索肿瘤学公司 (s)-5-氨基-3-(4-((5-氟-2-甲氧基苯甲酰胺基)甲基)苯基)-1-(1,1,1-三氟丙-2-基)-1h-吡唑-4-甲酰胺的喷雾干燥的分散体和制剂
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
JPS6041489A (ja) 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２
AU2882699A (en) 1998-02-27 1999-09-15 Watson Pharmaceuticals, Inc. Stabilizing composition for pharmaceutical dosage forms
JP2002275068A (ja) 2001-03-16 2002-09-25 Kyowa Hakko Kogyo Co Ltd アポトーシス誘導剤
EP1430053B1 (en) 2001-09-27 2006-10-25 SmithKline Beecham Corporation AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN
WO2003051847A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
FR2836915B1 (fr) 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
WO2004007676A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
NZ539193A (en) 2002-09-05 2008-04-30 Aventis Pharma Sa Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
BR0316606A (pt) 2002-12-12 2005-10-11 Aventis Pharma Sa Derivados de aminoindazóis e sua utilização como inibidores de quinases
US20040229880A1 (en) 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
DK1603570T5 (da) 2003-02-26 2013-12-09 Sugen Inc Aminoheteroarylforbindelser som proteinkinaseinhibitorer
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2007502329A (ja) 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
ATE517091T1 (de) 2003-09-26 2011-08-15 Exelixis Inc C-met-modulatoren und verwendungsverfahren
DE60324207D1 (de) 2003-10-24 2008-11-27 Oncalis Ag Verfahren zur identifizierung und/oder validierung von rezeptortyrosinkinase-inhibitoren
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1847532B1 (en) 2005-01-27 2013-06-05 Kyowa Hakko Kirin Co., Ltd. Igf-1r inhibitor
WO2006111035A1 (en) 2005-04-21 2006-10-26 Oncalis Ag Method for the identification of possibly harmful receptor tyrosine kinase (rtk) mutations and of inhibitors or medication directed against rtk mutantstitle
WO2006123113A2 (en) 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
BRPI0614809A2 (pt) 2005-08-09 2011-04-12 Johannes Gutenberg Universitaet Mainz sensibilização de cánceres de pulmão resistentes a fármaco a inibidores de proteìna cinase
CA2633584A1 (en) 2005-12-20 2007-07-05 Takeda Pharmaceutical Company Limited Glucokinase activators
DE102006030479A1 (de) 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
PL2041138T3 (pl) 2006-07-07 2014-11-28 Bristol Myers Squibb Co Pirolotriazyny jako inhibitory kinazy
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
ES2559528T3 (es) 2006-12-08 2016-02-12 Novartis Ag Compuestos y composiciones como inhibidores de proteína cinasa
JP2010512405A (ja) 2006-12-11 2010-04-22 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての化合物および組成物
JP5302896B2 (ja) * 2006-12-20 2013-10-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 癌治療のためのキナーゼ阻害剤としてのインダゾール誘導体
JP2010532758A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 組み合わせ抗癌療法
BRPI0814628B1 (pt) 2007-07-20 2022-04-05 Nerviano Medical Sciences S.R.L. Derivados ativos de indazol substituídos como inibidores da quinase
RU2495044C2 (ru) 2007-08-29 2013-10-10 Метилджен Инк. Ингибиторы активности протеинтирозинкиназы
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
CN102924479A (zh) 2011-08-09 2013-02-13 山东鲁北药业有限公司 一种星孢菌素类衍生物的半合成方法
CN104364391A (zh) 2012-02-08 2015-02-18 因赛特遗传学公司 用于诊断和治疗癌症的涉及ros1融合的方法和组合物
JP5823066B2 (ja) 2012-03-06 2015-11-25 ファイザー・インク 増殖性疾患の治療のための大環状誘導体
AU2013265288B2 (en) 2012-05-23 2017-12-21 Nerviano Medical Sciences S.R.L. Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
BR112015006537A2 (pt) 2012-09-28 2017-07-04 Oncoethix Sa dispersão sólida, formulação farmacêutica, cápsula farmacêutica, e, tablete farmacêutico
WO2014093750A1 (en) 2012-12-14 2014-06-19 Glaxosmithkline Llc Method of administration and treatment
DE102013012850A1 (de) * 2013-08-02 2015-02-05 Sew-Eurodrive Gmbh & Co Kg Elektromotor mit Rotorwelle und Gehäuseteil
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
JP6499672B2 (ja) 2014-05-15 2019-04-10 アレイ バイオファーマ、インコーポレイテッド ＴｒｋＡキナーゼ阻害剤としての１−（（３Ｓ，４Ｒ）−４−（３−フルオロフェニル）−１−（２−メトキシエチル）ピロリジン−３−イル）−３−（４−メチル−３−（２−メチルピリミジン−５−イル）−１−フェニル−１Ｈ−ピラゾール−５−イル）尿素
WO2015184443A1 (en) * 2014-05-30 2015-12-03 The Regents Of The University Of Colorado Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
EP3154549A1 (en) 2014-06-13 2017-04-19 Oncoethix GmbH Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds
KR102595599B1 (ko) 2014-12-02 2023-11-02 이그니타, 인코포레이티드 신경모세포종의 치료를 위한 병용
EP3227686A4 (en) 2014-12-03 2018-08-29 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
AU2016270321B2 (en) 2015-05-29 2020-09-10 Ignyta, Inc. Compositions and methods for treating patients with RTK mutant cells
EA201792679A1 (ru) 2015-06-01 2018-06-29 Локсо Онколоджи, Инк. Способы диагностики и лечения злокачественной опухоли
AU2016344058A1 (en) 2015-10-26 2018-05-17 Array Biopharma Inc. Point mutations in Trk inhibitor-resistant cancer and methods relating to the same
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
US10398693B2 (en) 2017-07-19 2019-09-03 Ignyta, Inc. Pharmaceutical compositions and dosage forms
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型

Also Published As

Publication number Publication date
AU2015220832B2 (en) 2020-02-27
CA2933623C (en) 2022-05-17
KR102634514B1 (ko) 2024-02-07
JP2017506255A (ja) 2017-03-02
EA033457B1 (ru) 2019-10-31
US10561651B2 (en) 2020-02-18
IL246544A0 (en) 2016-08-31
KR20160117611A (ko) 2016-10-10
AU2015220832A1 (en) 2016-09-08
WO2015124697A1 (en) 2015-08-27
AU2015220832A2 (en) 2016-09-08
US20170007599A1 (en) 2017-01-12
PH12016501394A1 (en) 2017-02-20
TW201613593A (en) 2016-04-16
US20180333412A1 (en) 2018-11-22
NL301111I1 (es) 2021-06-23
CN106029073A (zh) 2016-10-12
US20150283132A1 (en) 2015-10-08
BR112016015818A2 (pt) 2017-08-08
NL301111I2 (nl) 2021-09-27
ES2856231T3 (es) 2021-09-27
EA201691151A1 (ru) 2017-01-30
EP3107541A1 (en) 2016-12-28
PL3107541T3 (pl) 2021-09-20
MX2016010519A (es) 2016-11-16
UA118773C2 (uk) 2019-03-11
US20190282564A1 (en) 2019-09-19
CA2933623A1 (en) 2015-08-27
TWI672141B (zh) 2019-09-21
EP3107541B1 (en) 2020-12-23
JP6636933B2 (ja) 2020-01-29
US10231965B2 (en) 2019-03-19
SG11201605816TA (en) 2016-08-30
US10682348B2 (en) 2020-06-16
IL246544B (en) 2019-12-31
NZ722405A (en) 2021-03-26
EP3834827A1 (en) 2021-06-16
KR20220165787A (ko) 2022-12-15

Similar Documents

Publication Publication Date Title
CL2016001507A1 (es) Compuestos para tratar pacientes con células cancerosas mutantes ros1
SV2018005677A (es) Mutaciones puntuales en cancer resistente a trk y metodos relacionados con las mismas
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
BR112018011133A2 (pt) alvos terapêuticos para a correção do gene humano de distrofina por edição de gene e métodos de uso
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
PH12017501942A1 (en) Oncolytic adenovirus encoding a b7 protein
CY1125279T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
NZ735998A (en) Heterocyclic compounds as lsd1 inhibitors
EA201891192A1 (ru) Средства и способы лечения миопатий, связанных с титином, и других титинопатий
BR112018073329A2 (pt) combinação, composição farmacêutica, kit, método para tratar câncer, método para reduzir um nível de células, método para aumentar a atividade, método para aumentar a citotoxicidade, método para reduzir metástase
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
CL2016002971A1 (es) Combinación.
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
EA201691354A1 (ru) Терапевтические ингибирующие соединения
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2018000070A1 (es) Modulares de diaciglicerol aciltransderasa 2 (dgta2)
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
BR112015012295A8 (pt) Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
SA518392005B1 (ar) تحديد خصائص التسلسل العميق للأورام
EA201270361A1 (ru) Птеридины и их применение в качестве агрохимикатов
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
TR201905233T4 (tr) Dirençli bakteriyel enfeksiyonların tedavisine yönelik kombinasyon tedavisi.